RegisterLogin

Baricitinib

CAT: 400-SIH-587-25MGSize: 25 mgDry Ice: NoHazardous: No
25 mgSelected
PRICE
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1Product image 2
1 / 2
Background
Baricitinib acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2, therby reducing cytokine release and suppressing the innate and adaptive immune systems. It was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.
Description
Kinase inhibitor
CAS Number
1187594-09-7
Product Name Alternative
1- (Ethylsulfonyl) -3-[4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl) -1H-pyrazol-1-yl]-3-azetidineacetonitrile, INCB028050, LY3009106
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cell Signaling | Growth Factors | TNF
Purity
>98% (HPLC) ; NMR (Conforms)
Weight
0.005
Format
White to off-white powder
Solubility
May be dissolved in DMSO (30 mg/ml); or DMF (50 mg/ml)
Molecular Formula
C16H17N7O2S
Molecular Weight
371.4
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1."Summary of opinion for Olumiant" (PDF). European Medicines Agency (EMA). 15 December 2016. 2. Cantini F., et al. (2020) J. Infect. DOI: 10.1016/j.jinf.2020.04.017

Related Products

CatalogName

Alternative Products

CatalogName
MBS3600642-01Baricitinib
M10642-01Baricitinib
RM-B180300-01Baricitinib
GW9910-10mgBaricitinib
bs-75615C-01Baricitinib
sc-364730Baricitinib
205893Baricitinib
C08906-01Baricitinib
162734Baricitinib
abx076867-01Baricitinib

Popular Products